Literature DB >> 6446260

Treatment of experimental Haemophilus influenzae type b meningitis with 1-oxa-beta-lactam (LY127935).

C S Cordera, R S Pekarek.   

Abstract

1-Oxa-beta-lactam (LY127935) (Shionogi 6059-S) is a new type beta-lactam antibiotic having a broad spectrum of antibacterial activity. It is highly active against ampicillin-resistant strains of Haemophilus influenzae exhibiting minimal inhibitory concentrations as low as 0.06 microgram/ml. This compound also has the ability to penetrate into the cerebrospinal fluid of both normal and infected infant rats and attains approximately 10% of the corresponding blood levels. LY127935 was evaluated for its ability to treat ampicillin-resistant H. influenzae meningitis in an established experimental model using infant rats. Rats with ampicillin-resistant H. influenzae meningitis were treated subcutaneously three times daily for 2 days with various dose levels of LY127935. When given in doses as low as 10 mg/kg, LY127935 sterilized the blood and cerebrospinal fluid in all rats examined at 1 and 5 days posttreatment. In contrast, ampicillin was not effective at this dose in eliminating H. influenzae from the blood and cerebrospinal fluid of infected rats. LY127935 was effective against experimental ampicillin-resistant H. influenzae meningitis in the dosages employed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446260      PMCID: PMC283768          DOI: 10.1128/AAC.17.2.258

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Haemophilus influenzae meningitis in infant rats after intranasal inoculation.

Authors:  E R Moxon; A L Smith; D R Averill; D H Smith
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Commentary: Immunization against Haemophilus influenzae.

Authors:  E A Mortimer
Journal:  Pediatrics       Date:  1973-11       Impact factor: 7.124

3.  Editorial: Should ampicillin be abandoned for treatment of Haemophilus influenzae disease?

Authors:  J D Nelson
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

4.  Haemophilus influenzae type B resistant to ampicillin. A report of two cases.

Authors:  W Khan; S Ross; W Rodriguez; G Controni; A K Saz
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

5.  Letter: Ampicillin-resistant Haemophilus influenzae meningitis.

Authors:  W J Thomas; J W McReynolds; C R Mock; D W Bailey
Journal:  Lancet       Date:  1974-02-23       Impact factor: 79.321

6.  Bacterial meningitis. A symposium.

Authors:  D H Smith; D L Ingram; A L Smith; F Gilles; M J Bresnan
Journal:  Pediatrics       Date:  1973-10       Impact factor: 7.124

7.  Pathogenesis of meningitis. VIII. Cerebrospinal fluid and blood concentrations of methicillin, cephalothin, and cephaloridine in experimental pneumococcal meningitis.

Authors:  S Oppenheimer; H N Beaty; R G Petersdorf
Journal:  J Lab Clin Med       Date:  1969-04

8.  Aminoglycoside therapy of gram-negative bacillary meningitis.

Authors:  A B Kaiser; Z A McGee
Journal:  N Engl J Med       Date:  1975-12-11       Impact factor: 91.245

9.  Ampicillin and an ester in experimental Hemophilus influenzae meningitis.

Authors:  J A Bodine; L J Strausbaugh; M A Sande
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

10.  Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation.

Authors:  A L Smith; D H Smith; D R Averill; J Marino; E R Moxon
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more
  8 in total

1.  Update on antibiotic resistance of Haemophilus influenzae in Canada.

Authors:  D W Scheifele
Journal:  Can Med Assoc J       Date:  1982-08-01       Impact factor: 8.262

2.  Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats.

Authors:  Y H Tsai; M Bies; F Leitner; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Comparative in vitro and in vivo activity of temocillin (BRL 17421) and ampicillin against Haemophilus influenzae type b.

Authors:  R Yogev; W Glogowski; E Connor
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

5.  Moxalactam penetration into cerebrospinal fluid in patients with bacterial meningitis.

Authors:  J Modai; M Wolff; J Lebas; A Meulemans; C Manuel
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  In vitro activity of moxalactam alone and in combination with penicillin against common meningeal pathogens.

Authors:  P H Azimi; M G Dunphy
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

7.  Clinical evaluation of moxalactam.

Authors:  W K Livingston; A M Elliott; W E Dismukes; C K Avent; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

8.  Penetration of ocular tissues and fluids by moxalactam in rabbits with staphylococcal endophthalmitis.

Authors:  A Kane; M Barza; J Baum
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.